Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: Associations with disease activity

Acta Neurologica Scandinavica

Volumn 112, Issue 6, 2005, Pages 395-402

  Hollsberg P ^a   Kusk, M ^a   Bech, E ^b   Hansen, H J ^b   Jakobsen, J ^b   Haahr, S ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Herpesvirus; Multiple sclerosis; Polymerase chain reaction; Saliva; Valacyclovir

Indexed keywords

PLACEBO; VALACICLOVIR; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 6; IMMUNE RESPONSE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ULTRACENTRIFUGATION; VIRUS IDENTIFICATION;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS 6, HUMAN; HUMANS; MALE; MULTIPLE SCLEROSIS; SALIVA; STATISTICS; TREATMENT OUTCOME; VALINE; VIRAL LOAD;

EID: 28144448320     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00516.x     Document Type: Article

References (41)

1. MARTIN R, MCFARLAND HF, MCFARLIN DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-87.
2. COMPSTON A. The genetics of multiple sclerosis. Clin Chem Lab Med 2000;38:133-5.
3. HAAHR S, HOLLSBERG P. The ability of candidate viruses to explain epidemiological findings in multiple sclerosis. In: Hommes OR, Wekerlee H, Clanet M, eds. Genes and viruses in multiple sclerosis. Amsterdam: Elsevier Science B.V., 2001;163-84.
4. SIBLEY WA, BAMFORD CR, CLARK K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-5.
5. ANDERSEN O, LYGNER PE, BERGSTROM T, ANDERSSON M, VAHLNE A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993;240:417-22.
6. EDWARDS S, ZVARTAU M, CLARKE H, IRVING W, BLUMHARDT LD. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:736-41.
7. BULJEVAC D, FLACH HZ, HOP WC et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125(Pt 5):952-60.
8. HUNTER SF, HAFLER DA. Ubiquitous pathogens: links between infection and autoimmunity in MS? Neurology 2000;55:164-5.
9. LINDBERG C, ANDERSEN O, VAHLNE A, DALTON M, RUNMARKER B. Epidemiological investigations of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 1991;10:62-5.
10. HAAHR S, KOCH-HENRIKSEN N, MØLLER-LARSEN A, ERIKSEN LS, ANDERSEN HMK. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler 1995;1:73-7.
11. HAAHR S, PLESNER AM, VESTERGAARD BF, HOLLSBERG P. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand 2004;109:270-5.
12. ALOTAIBI S, KENNEDY J, TELLIER R, STEPHENS D, BANWELL B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004;291:1875-9.
13. MUNCH M, RIISOM K, CHRISTENSEN T, MØLLER-LARSEN A, HAAHR S. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients? Acta Neurol Scand 1998;97:171-4.
14. ASCHERIO A, MUNGER KL, LENNETTE ET et al. Epstein-Barr virus antibodies and risk of multiple sclerosis - a prospective study. JAMA 2001;286:3083-8.
15. LEVIN LI, MUNGER KL, RUBERTONE MV et al. Multiple sclerosis and Epstein-Barr virus. JAMA 2003;289:1533-6.
16. WANDINGER KP, JABS W, SIEKHAUS A et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000;55:178-84.
17. LYCKE J, SVENNERHOLM B, HJELMQUIST E et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996;243:214-24.
18. BECH E, LYCKE J, GADEBERG P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002;58:31-6.
19. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research pro-tocols. Ann Neurol 1983;13:227-31.
20. SOLDAN SS, BERTI R, SALEM N et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997;3:1394-7.
21. CHALLONER PB, SMITH KT, PARKER JD et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995;92:7440-4.
22. AKHYANI N, BERTI R, BRENNAN MB et al. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis 2000;182:1321-5.
23. SOLDAN SS, LEIST TP, JUHNG KN, MCFARLAND HF, JACOBSON S. Increased lymphoproliferative response to human herpes-virus type 6A variant in multiple sclerosis patients. Ann Neurol 2000;47:306-13.
24. KIM JS, LEE KS, PARK JH, KIM MY, SHIN WS. Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients. Eur Neurol 2000;43:170-3.
25. ONGRADI J, RAJDA C, MARODI CL, CSISZAR A, VECSEI L. A pilot study on the antibodies to HHV-6 variants and HHV-7 in CSF of MS patients. J Neurovirol 1999;5:529-32.
26. ABLASHI DV, LAPPS W, KAPLAN M et al. Human herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report. Mult Scler 1998;4:490-6.
27. BERTI R, BRENNAN MB, SOLDAN SS et al. Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression. J Neurovirol 2002;8:250-6.
28. KHAN G, MIYASHITA EM, YANO B, BABCOCK GJ, THORLEYLAWSON DA. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 1996;5:173-9.
29. MIYASHITA EM, YANG B, LAM KM, CRAWTORD DH, THORLEY-LAWSON DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995;80:593-601.
30. BRAUN DK, DOMINGUEZ G, PELLETT PE. Human herpesvirus 6. Clin Microbiol Rev 1997;10:521-67.
31. IKUTA K, SATOH Y, HOSHIKAWA Y, SAIRENJI T. Detection of Epstein-Barr virus in salivas and throat washings in healthy adults and children. Microbes Infect 2000;2:115-20.
32. COHEN JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92.
33. TUGIZOV SM, BERLINE JW, PALEFSKY JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003;9:307-14.
34. BRAY PF, CULP KW, MCFARLIN DE et al. Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection. Neurology 1992;42:278-82.
35. WUCHERPFENNIG KW, STROMINGER JL. Molecular mimicry in T-cell-mediated autoimmunity - viral peptides activate human T-cell clones specific for myelin basic-protein. Cell 1995;80:695-705.
36. LANG HL, JACOBSEN H, IKEMIZU S et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;3:940-3.
37. SUTKOWSKI N, CONRAD B, THORLEY-LAWSON DA, HUBER BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001;15:579-89.
38. PENDER MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003;24:584-8.
39. VAN NOORT JM, BAJRAMOVIC JJ, PLOMP AC, VAN STIPDONK MJ. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol 2000;105:46-57.
40. OBEL N, HOIER-MADSEN M, KANGRO H. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS 1996;104:424-8.
41. GOTLIEB-STEMATSKY T, RANNON L, VONSOVER A, VARSANO N. Stimulation of antibodies to Epstein-Barr virus (EBV) in acute viral infections. Arch Virol 1978;57:199-204.